Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Programmed Cell Death 1 Ligand 1(PDL1, PD-L1)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Ended earlyNCT03515824
What this trial is testing

Study of MK-1697 in Participants With Advanced Solid Tumors (MK-1697-001)

Who this might be right for
NeoplasmsColorectal NeoplasmsHead and Neck Neoplasms
Merck Sharp & Dohme LLC 22
Early research (Phase 1)Study completedNCT03312842
What this trial is testing

A Phase Ia/Ib Study of CS1001 in Subjects With Advanced Solid Tumors

Who this might be right for
Advanced Cancer
CStone Pharmaceuticals 259
Testing effectiveness (Phase 2)Looking for participantsNCT06027086
What this trial is testing

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

Who this might be right for
Fibrolamellar Hepatocellular Carcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 27
Testing effectiveness (Phase 2)Looking for participantsNCT06839560
What this trial is testing

Evaluating the Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With VEX Metronomic Chemotherapy and Concurrent or Delayed Radiotherapy in Patients With Advanced HER2-Negative Breast Cancer With Brain Metastasis

Who this might be right for
Brain Metastasis From Advanced HER2-negative Breast Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 102
Testing effectiveness (Phase 2)Ended earlyNCT03606174
What this trial is testing

Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Who this might be right for
Urothelial CarcinomaUrothelial Carcinoma BladderUrothelial Carcinoma Ureter+2 more
Mirati Therapeutics Inc. 260
Large-scale testing (Phase 3)Study completedNCT02853331
What this trial is testing

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 861
Large-scale testing (Phase 3)Not Yet RecruitingNCT07763171
What this trial is testing

Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma

Who this might be right for
Gastroesophageal Adenocarcinoma
Gruppo Oncologico del Nord-Ovest 244
Not applicableLooking for participantsNCT04294771
What this trial is testing

JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint Inhibitors

Who this might be right for
MyocarditisCardiomyopathiesHeart Diseases+3 more
Groupe Hospitalier Pitie-Salpetriere 500,000
Large-scale testing (Phase 3)Active Not RecruitingNCT04960709
What this trial is testing

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Who this might be right for
Muscle Invasive Bladder Cancer
AstraZeneca 712
Large-scale testing (Phase 3)Looking for participantsNCT06952504
What this trial is testing

Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

Who this might be right for
Endometrial Cancer
Merck Sharp & Dohme LLC 1,123
Testing effectiveness (Phase 2)Study completedNCT01846416
What this trial is testing

Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]

Who this might be right for
Non-Small Cell Lung Cancer
Genentech, Inc. 138
Early research (Phase 1)Ended earlyNCT04135352
What this trial is testing

Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)

Who this might be right for
Neoplasm Metastasis
Merck Sharp & Dohme LLC 35
Testing effectiveness (Phase 2)WithdrawnNCT03238638
What this trial is testing

Epacadostat + Pembrolizumab in Head and Neck Cancer Patients, Who Failed Prior PD-1/PD-L1 Therapy

Who this might be right for
Head and Neck Cancer
University of Chicago
Testing effectiveness (Phase 2)Study completedNCT03891238
What this trial is testing

Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES Study

Who this might be right for
Metastatic or Locally Advanced PD-L1 Positive Urothelial Cancer
Consorzio Oncotech 67
Large-scale testing (Phase 3)Study completedNCT02302807
What this trial is testing

Atezolizumab Compared With Chemotherapy in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer [IMvigor211]

Who this might be right for
Bladder Cancer
Hoffmann-La Roche 931
Testing effectiveness (Phase 2)Looking for participantsNCT07579221
What this trial is testing

Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
M.D. Anderson Cancer Center 17
Large-scale testing (Phase 3)Active Not RecruitingNCT03164616
What this trial is testing

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Who this might be right for
Non Small Cell Lung Cancer NSCLC
AstraZeneca 1,186
Very early researchUnknownNCT03060343
What this trial is testing

Zeushield Cytotoxic T Lymphocytes (Z-CTLs) for Relapsed or Refractory Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
Yu Fenglei 10
Early research (Phase 1)Study completedNCT02605915
What this trial is testing

Safety and Pharmacokinetics of Atezolizumab Combination Treatments in Participants With HER2-Positive and HER2-Negative Breast Cancer

Who this might be right for
HER2-Positive Metastatic Breast CancerHER2-Negative Metastatic Breast CancerLocally Advanced or Early Breast Cancer
Hoffmann-La Roche 98
Testing effectiveness (Phase 2)UnknownNCT04726215
What this trial is testing

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer
CellSight Technologies, Inc. 50
Next Page